New drugs don’t make it any easier to treat non-valvular atrial fibrillation
With the recent heavy marketing of the relatively new novel oral anticoagulants dabigatran, rivaroxaban, and apixaban, a new marketing phrase has been born: "non-valvular" atrial fibrillation. What, exactly, is "non-valvular" atrial fibrillation? Is ...